BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 33685865)

  • 21. EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Wang F; Li C; Wu Q; Lu H
    Transl Cancer Res; 2020 Apr; 9(4):2982-2991. PubMed ID: 35117654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
    Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
    J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies 
in Non-small Cell Lung Cancer].
    Wang Y; Chu T
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with
    Xu CW; Wang WX; Wang D; Wang QM; Pu XX; Zhu YC; Huang JH; Yu ZY; Cui ZL; Chen XH; Li JL; Fang Y; Wang H; Zhuang W; Lan SJ; Cai X; Zhang YB; Gao WB; Wang LP; She KL; Rao CZ; Zhou YF; Fang MY; Miao LY; Lei L; Lv TF; Song Y
    Transl Lung Cancer Res; 2020 Oct; 9(5):1853-1861. PubMed ID: 33209607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.
    Zhang M; Nie L; Cheng Y
    Thorac Cancer; 2021 Oct; 12(20):2803-2806. PubMed ID: 34382340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
    Xu M; Luo J; Xu R
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):151-157. PubMed ID: 36872053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with
    Shi C; Xing R; Li M; Feng J; Sun R; Wei B; Guo Y; Ma J; Wang H
    Front Oncol; 2022; 12():949304. PubMed ID: 36119499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations.
    Ma T; Jiao J; Huo R; Li X; Fang G; Zhao Q; Liu W; Han X; Xi C; Wang Y; Shang Y
    Front Oncol; 2022; 12():922899. PubMed ID: 35992815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
    Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
    J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Gao X; Wei XW; Zheng MY; Chen ZH; Zhang XC; Zhong WZ; Yang JJ; Wu YL; Zhou Q
    J Thorac Dis; 2020 Oct; 12(10):5822-5832. PubMed ID: 33209414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
    Watanabe N; Horio Y; Fujiwara Y
    Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
    Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic
    Choudhury NJ; Schneider JL; Patil T; Zhu VW; Goldman DA; Yang SR; Falcon CJ; Do A; Nie Y; Plodkowski AJ; Chaft JE; Digumarthy SR; Rekhtman N; Arcila ME; Iasonos A; Ou SI; Lin JJ; Drilon A
    JTO Clin Res Rep; 2021 Jul; 2(7):100187. PubMed ID: 34590036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.